These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 15480830)

  • 1. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
    Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
    Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
    Saeger W; Lüdecke B; Lüdecke DK
    Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.
    Lath R; Chacko G; Chandy MJ
    Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
    Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
    Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
    Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
    Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas.
    Gejman R; Swearingen B; Hedley-Whyte ET
    Hum Pathol; 2008 May; 39(5):758-66. PubMed ID: 18439942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
    Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
    Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
    Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
    Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
    Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD147 expression in pituitary adenomas and its significance for clinical outcome.
    Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G
    Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
    Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S
    J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.
    Losa M; Franzin A; Mangili F; Terreni MR; Barzaghi R; Veglia F; Mortini P; Giovanelli M
    Neurosurgery; 2000 Dec; 47(6):1313-8; discussion 1318-9. PubMed ID: 11126902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic correlates of giant pituitary adenomas.
    Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
    J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
    Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
    Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients.
    Mazal PR; Czech T; Sedivy R; Aichholzer M; Wanschitz J; Klupp N; Budka H
    Clin Neuropathol; 2001; 20(4):163-71. PubMed ID: 11495005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
    Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
    Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of RCAS1 in human pituitary adenomas.
    Umeoka K; Sanno N; Oyama K; Tahara S; Kurotani R; Ikuyama S; Nakashima M; Watanabe T; Osamura RY; Teramoto A
    Mod Pathol; 2001 Dec; 14(12):1232-6. PubMed ID: 11743045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indices of apoptosis and proliferation as potential prognostic markers in non-functioning pituitary adenomas.
    Ibrahim AE; Pickering RM; Gawne-Cain ML; King S; Lees PD; Ellison DW
    Clin Neuropathol; 2004; 23(1):8-15. PubMed ID: 14986928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
    Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
    Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67.
    Knosp E; Kitz K; Perneczky A
    Neurosurgery; 1989 Dec; 25(6):927-30. PubMed ID: 2601824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.